Bclaf1 binds to SPOP, thereby inhibiting PD-L1 ubiquitination and degradation and making cancer cells sensitive to checkpoint therapy, suggesting that Bclaf1 is a novel therapeutic target for enhancing anti-tumor immunity in HCC (Yu et al., 2024). Here, BCLAF1 is linked to hepatocellular carcinoma.